作者: Aminah Jatoi , James R. Jett , Jeff Sloan , Paul Novotny , Joyce Ford
DOI: 10.1007/S00520-004-0638-X
关键词:
摘要: Background Weight loss predicts a poor prognosis for patients with non-small-cell lung cancer. Tumor necrosis factor α (TNFα) is mediator of this weight loss, yet no studies have tested infliximab, an IgG monoclonal antibody that blocks the binding TNFα to its p55 and p75 receptors, indication. The safety pharmacokinetics infliximab in combination docetaxel, commonly used chemotherapy agent cancer, were explored pilot study.